** Shares of Australia's Prescient Therapeutics PTX.AX rise as much as 11.2% to A$0.099, their highest since early December 2023

** Clinical-stage oncology firm says that the European Clinical Trials Information System (CTIS) granted authorisation to initiate clinical trial for PTX-100 in patients with relapsed/refractory Cutaneous T-cell Lymphoma

** PTX-100 is a therapy targeting cancer growth pathways

** Co says approval enables activation of trial sites in Italy

** About 5 mln shares change hands, nearly 2.2x 30-day average

** PTX up 94% YTD

(Reporting by Keshav Singh Chundawat in Bengaluru)

((Keshav.singhchundawat@thomsonreuters.com))